FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.

ABSTRACT: In December 2019, a novel SARS-CoV-2 coronavirus emerged, causing an outbreak of life-threatening pneumonia in the Hubei province, China, and has now spread worldwide, causing a pandemic. The urgent need to control the disease, combined with the lack of specific and effective treatment modalities, call for the use of FDA-approved agents that have shown efficacy against similar pathogens. Chloroquine, remdesivir, lopinavir/ritonavir or ribavirin have all been successful in inhibiting SARS-CoV-2 in vitro. The initial results of a number of clinical trials involving various protocols of administration of chloroquine or hydroxychloroquine mostly point towards their beneficial effect. However, they may not be effective in cases with persistently high viremia, while results on ivermectin (anothe

SUBMITTER: Drozdzal S 

PROVIDER: S-EPMC7362818 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature